Prosight Management’s AbbVie ABBV Stock Holding History

Prosight Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,800	Closed	-$2.67M	–	37
2021 Q3	$2.67M	Buy	+24,800	New	+$2.83M	1.47%	26
2020 Q2	–	Sell	-16,030	Closed	-$1.22M	–	53
2020 Q1	$1.22M	Buy	+16,030	New	+$1.37M	0.57%	32
2019 Q4	–	Sell	-39,000	Closed	-$2.95M	–	39
2019 Q3	$2.95M	Buy	+39,000	New	+$2.67M	1.64%	20

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Prosight Management's ABBV Position: Q4 2021 in Review

Prosight Management sold out of AbbVie (ABBV) in Q4 2021, closing a stake of 24,800 shares — an estimated $2.67M sold.

Prosight Management first reported a position in ABBV in Q3 2019 and held it in 3 quarters. The position peaked at $2.95M in Q3 2019. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.

Prosight Management reported no remaining AbbVie position as of Q4 2021 after selling out during the quarter.
Prosight Management sold 24,800 AbbVie shares in Q4 2021, an estimated $2.67M.
Prosight Management first reported a position in AbbVie in Q3 2019 and held it in 3 quarters.
Prosight Management's AbbVie position peaked at $2.95M in Q3 2019.
2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.

Based on Prosight Management's 13F filing for Q4 2021, filed 14 Feb 2022.